News Releases

MEDIA INVITED: Immunomic Therapeutics, Inc., Talks Vital Vaccine Technology Advancement at Biotech Showcase 2016

HERSHEY, Pa. and ROCKVILLE, Md., Jan. 12, 2016 /PRNewswire/ -- Following one of the largest upfront payments for rights to an early-stage allergy vaccine technology, Immunomic Therapeutics, Inc. (ITI) will share the projections for their potentially game-changing DNA vaccine platform with investors at the Biotech Showcase™ 2016 on Wednesday.

The talk will focus on the LAMP-vax™ platform, a unique vaccine technology that relies on the body's own natural biochemistry to increase vaccine effectiveness. Late last year, the Japanese firm, Astellas Pharma purchased the rights to apply LAMP-vax to human allergy worldwide for $300M. Astellas is working to produce a pipeline of allergy therapies, including a LAMP-vax based vaccine for peanut allergy, and ITI is now taking aim at cancer immunology. On Wednesday, ITI's Chief Financial Officer, Eric Winzer, will share LAMP-vax development plans and discuss anticipated implications on the future healthcare landscape.


Eric Winzer, CFO, Immunomic Therapeutics, Inc.


Biotech Showcase 2016: LAMP-vax Vaccines, Next Generation Immunotherapies


11:45 a.m. on Wed., Jan. 13, 2016


E-Davidson, Fourth Floor

Parc 55

55 Cyril Magnin Street

San Francisco, CA 94102


About LAMP-vax platform

The LAMP-vax platform is a breakthrough technology that has the potential to fundamentally improve the use of vaccines across a wide variety of diseases.  LAMP-vax is a next-generation DNA vaccine that stimulates an immune response against a particular protein by injecting the DNA encoding the protein rather than the protein itself.  However, unlike older, conventional DNA vaccines, LAMP-vax includes the DNA sequence encoding Lysosomal Associated Membrane Protein (LAMP).  This allows DNA vaccines developed, based on the LAMP-vax platform, to utilize the body's natural biochemistry to develop a more complete immune response compared to conventional DNA vaccines.  Unlike conventional DNA vaccines that primarily elicit a cytotoxic T cell immune response, vaccines developed using LAMP-vax initiate a more complete immune response, including antibody production, cytokine release and critical immunological memory.  The ability to activate a complete immune response gives LAMP-vax technology potential across a number of diseases, including cancer immunotherapy, allergy and infectious diseases.

About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company dedicated to pioneering vaccines that transform lives.  Headquartered in Hershey, PA with lab facilities in Rockville, MD, ITI is developing next-generation vaccines based on patented LAMP Technology.  Its LAMP-vax vaccine platform significantly increases the immune response to nucleic acid vaccines and simplifies vaccine design and delivery for safer, more cost-effective therapies.  LAMP constructs have been validated in human clinical trials for cancer and have been applied to targets like allergy, cancer and infectious diseases.  Immunomic Therapeutics' vision is to have regulatory approved products in pollen allergy, food allergy, cancer, and animal health. For information about Immunomic Therapeutics and LAMP Technology, visit


SOURCE Immunomic Therapeutics, Inc.

For further information: Immunomic Therapeutics, Inc., PR/Marketing (US), 717-327-1919